InteRNA Technologies BV

📍 Utrecht, Netherlands👥 12 employees💰 Last funded Jan 2019
Biotechnology Research🌐 interna-technologies.com
Website LinkedIn
In the course of 2022, InteRNA concluded the first part of its Phase 1a clinical trial with lead candidate INT-1B3 showing a positive safety profile. Unfortunately, due to lack of capital InteRNA was not able to start the second part of this trial for which the necessary regulatory approvals were in place. Despite also the already obtained clearance from the FDA for the Phase 1b/2a trial, the outlook on a combinatory trial with one of the leading PD1 inhibitors in the immune-oncology marketplace and a positive FTO analysis, InteRNA has not been able to attract further funding in the distressed financing climate and was forced to cease operations at the end of Q1-2023. Here we wish to extend our sincere gratitude to the participating patients and their families, as well as our employees, board members, clinical and scientific advisors, investors and partners for their support throughout our journey. It is a pity that INT-1B3 with its promising and unique Mode of Action did not get the chance to be validated in a clinical trial for its efficacy.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Other investors· 1
?
Board Observer
Jan 2019
Frequently asked questions
Who invested in InteRNA Technologies BV?
InteRNA Technologies BV has 1 investors on record on gritt.io.
When did InteRNA Technologies BV last raise funding?
The most recent investment in InteRNA Technologies BV recorded on gritt.io was in January 2019.
What industry is InteRNA Technologies BV in?
InteRNA Technologies BV operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is InteRNA Technologies BV based?
InteRNA Technologies BV is headquartered in Utrecht, Netherlands.